Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 18/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215903 | 1.00 | CPB2 (0.62) | CPB2BACE1CYP3A4CPB1 | |
| SCHEMBL3191954 | 0.86 | FOLH1 (0.49) | CPB2BACE1CYP3A4CPB1 | |
| SCHEMBL3199506 | 0.85 | CPB2 (0.68) | CPB2 | |
| SCHEMBL3214045 | 0.83 | CPB2 (0.76) | CPB2CYP3A4CPB1 | |
| SCHEMBL3199974 | 0.82 | CPB2 (0.59) | CPB2CYP3A4CPB1 | |
| SCHEMBL3192687 | 0.81 | CPB2 (0.76) | CPB2CYP3A4CPB1 | |
| SCHEMBL3199942 | 0.80 | CPB2 (0.63) | CPB2 | |
| SCHEMBL3217585 | 0.80 | CPB2 (0.84) | CPB2CYP3A4CPB1 | |
| SCHEMBL27781419 | 0.80 | CPB2 (0.84) | CPB2CYP3A4CPB1 | |
| SCHEMBL8176076 | 0.80 | CYP3A4 (0.59) | BACE1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | claimed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | CPB2 61/4885BACE1 729/4885CYP3A4 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.